Rinat, a spinoff of Genentech, had been in a bidding war to partner with one of nine interested pharmaceutical firms for a promising but very early stage drug candidate to treat Alzheimer's.
Rinat, a spinoff of Genentech (nyse: DNA - news - people ), had been in a bidding war to partner with one of nine interested pharmaceutical firms for a promising but very early stage drug candidate to treat Alzheimer's.
But that doesn't prevent the heads of Wall Street firms such as Merrill Lynch, Morgan Stanley and Citigroup from rooting for one candidate over another based on expectations of economic performance.